Shapiro, A.M.J., Ricordi, C., Hering, B.J., Auchincloss, H., Lindblad, R., Robertson, R.P., Secchi, A., Brendel, M.D., Berney, T., Brennan, D.C., Cagliero, E., Alejandro, R., Ryan, E.A., DiMercurio, B., Morel, P., Polonsky, K.S., Reems, J.A., Bretzel, R.G., Bertuzzi, F., Froud, T., Kandaswamy, R., Sutherland, D.E.R., Eisenbarth, G., Segal, M., Preiksaitis, J., Korbutt, G.S., Barton, F.B., Viviano, L., Seyfert-Margolis, V., Bluestone, J. and Lakey, J.R.T. (2006) International Trial of the Edmonton Protocol for Islet Transplantation. The New England Journal of Medicine, 355, 1318-1330.
https://doi.org/10.1056/NEJMoa061267

has been cited by the following article:

• TITLE: Long Term Benefit of Autologous Bone Marrow Stem Cell Transplantation without Immunosuppression in Chronic Type 1 Diabetic Patients

  AUTHORS: Alejandro Mesples, Yun Zhang, Xiang Hu

  KEYWORDS: Type 1 Diabetes, Bone Marrow Transplantation, Bone Marrow Stem Cells

  JOURNAL NAME: Stem Cell Discovery, Vol.10 No.1, January 30, 2020

  ABSTRACT: Background:Autologous bone marrow stem cell transplantation without immune suppression has been proposed as a safe and efficient therapeutic option to replace β-cell mass destroyed by specific antibodies in chronic type 1 diabetes but we have not scientific information about how long the metabolic stability is maintained. Material and Method: From 2010 to 2014, were included 134 chronic type 1 diabetics patients (p.) in an autologous bone marrow stem cell transplantation protocol, stimulated with filgrastim, without immune suppression, c peptide Results:C peptide, 6 months after transplantation more than 0.9 ng/ml in 61 patients (45%) (P = 0.001, CI = 95%). At 12 months 50 patients (37%) (P = 0.001, CI = 95%). At 24 months 53 patients (39%) (P = 0.001, CI = 95%). At 36 months 51 patients (38%) (P = 0.001, CI = 95%). A1C before transplant, Conclusion:Autologous bone marrow stem cell transplantation, without immunosuppression, improves pancreatic function and metabolic control without new immune reaction after three years of follow up in chronic type 1 diabetic patients.